All cancer tissue phenotypes are initiated by deregulated signalling mechanisms in cancer cells. Signalling mechanism are also the largest target mechanism entity for targeted cancer therapies. Recent data further strongly indicate that cancer therapy resistance is initiated by non-genetic signalling rewiring via post-translational regulation of proteins involved in signalling networks, and transcriptional gene regulation. 

However, regardless of decades of research, our global understanding of how cancer cell signalling circuits are controlled, and how they determine cancer progression and therapy resistance is still far from complete. 

This conference will focus on basic mechanisms controlling cancer cell signalling circuits at the epigenome, transcriptome, proteome and phosphoproteome levels. The talks will also focus on therapeutic targeting of cancer cell signalling circuits by conventional and emerging pharmacological strategies.